Patients
A total of 108 consecutive patients who met Class I or IIa indications
for pacemaker therapy and intended to receive MicraTMleadless pacemaker implantation in the RV mid-septum were prospectively
enrolled from December 18, 2019 to June 17, 2021. All patients were
randomized to the radiography group (N =81) or the non-radiography group
(N =27) in a 3:1 format. The 3:1 randomization was used for allowing
more patients to receive mid-septal pacing. The exclusion criteria were
as follows: (1) presence of thrombosis or cancer embolus in the inferior
vena cava (IVC) or portal vein; (2) presence of bilateral femoral vein
stenosis or tortuosity that could cause failure to accommodate the
MicraTM pacemaker delivery system; (3) inability to
tolerate heparinization or allergy to heparin; (4) presence of implanted
devices that interfered with the MicraTM pacemaker
delivery system, such as IVC filters or tricuspid mechanical valve
replacement; (5) presence of severe renal insufficiency (glomerular
filtration rate <30 mL/min) or iodine allergy; (6) acute phase
of myocardial infarction, and (7) contraindications for CT scan or
contrast agents. All patients signed an informed consent form prior to
the surgical procedure. This study was approved by the Ethics Committee
of the First Affiliated Hospital of
Xinjiang Medical University (ethical approval number: K201912-10) and
registered in China Clinical Trial Registry (ChiCTR2100051374). Th data
that support the findings of this study are available from the
corresponding author on reasonable request